Apogee Competitors
| APGE Stock | 65.51 4.47 6.39% |
Apogee Therapeutics vs Disc Medicine Correlation
Very good diversification
The correlation between Apogee Therapeutics Common and IRON is -0.35 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Apogee Therapeutics Common and IRON in the same portfolio, assuming nothing else is changed.
Moving together with Apogee Stock
| 0.76 | ENTA | Enanta Pharmaceuticals Earnings Call This Week | PairCorr |
| 0.63 | FHTX | Foghorn Therapeutics | PairCorr |
Moving against Apogee Stock
| 0.7 | HUMA | Humacyte | PairCorr |
| 0.46 | AVH | Avita Medical | PairCorr |
| 0.46 | DNA | Ginkgo Bioworks Holdings | PairCorr |
| 0.38 | MYGN | Myriad Genetics | PairCorr |
| 0.36 | EVAX | Evaxion Biotech AS | PairCorr |
Apogee Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Apogee Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Apogee and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Apogee Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Apogee Stock performing well and Apogee Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Apogee Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CNTA | 2.31 | 0.05 | 0.01 | 0.22 | 2.67 | 4.97 | 26.54 | |||
| XENE | 1.60 | (0.03) | 0.00 | (0.07) | 0.00 | 3.78 | 10.56 | |||
| AAPG | 2.51 | (0.50) | 0.00 | (2.48) | 0.00 | 5.25 | 16.72 | |||
| RARE | 2.97 | (0.40) | 0.00 | (0.21) | 0.00 | 7.73 | 51.23 | |||
| CELC | 2.39 | 0.54 | 0.23 | 1.13 | 2.07 | 6.70 | 17.89 | |||
| ZLAB | 1.89 | (0.69) | 0.00 | (2.20) | 0.00 | 4.56 | 10.32 | |||
| CGON | 2.91 | 0.31 | 0.10 | 0.46 | 2.59 | 5.15 | 33.66 | |||
| LEGN | 2.29 | (0.87) | 0.00 | 7.17 | 0.00 | 3.83 | 19.65 | |||
| SLNO | 2.83 | (0.77) | 0.00 | (1.12) | 0.00 | 5.16 | 28.47 | |||
| IRON | 1.98 | (0.19) | 0.00 | 1.01 | 0.00 | 4.33 | 14.87 |
Cross Equities Net Income Analysis
Compare Apogee Therapeutics and related stocks such as Centessa Pharmaceuticals, Xenon Pharmaceuticals, and Ascentage Pharma Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CNTA | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (10.7 M) | (381.9 M) | (216.2 M) | (151.1 M) | (235.8 M) | (212.2 M) | (222.8 M) |
| XENE | (12 M) | (12 M) | (4.3 M) | 12 M | 13 M | (15.8 M) | (23 M) | (30.7 M) | (34.5 M) | (41.6 M) | (28.8 M) | (78.9 M) | (125.4 M) | (182.4 M) | (234.3 M) | (210.9 M) | (200.4 M) |
| AAPG | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (118.5 M) | (345.3 M) | (1.5 B) | (677.6 M) | (782.4 M) | (882.9 M) | (925.6 M) | (405.4 M) | (364.9 M) | (383.1 M) |
| RARE | (6.8 M) | (6.8 M) | (16.3 M) | (35.1 M) | (59.8 M) | (145.6 M) | (245.9 M) | (302.1 M) | (197.6 M) | (402.7 M) | (186.6 M) | (454 M) | (707.4 M) | (606.6 M) | (569.2 M) | (512.3 M) | (486.7 M) |
| CELC | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (3.3 M) | (6.3 M) | (7.5 M) | (7.4 M) | (9.5 M) | (29.6 M) | (40.4 M) | (63.8 M) | (111.8 M) | (100.6 M) | (95.6 M) |
| ZLAB | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (37.5 M) | (50.4 M) | (139.1 M) | (183.4 M) | (268.9 M) | (704.5 M) | (443.3 M) | (334.6 M) | (257.1 M) | (231.4 M) | (243 M) |
| CGON | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (35.4 M) | (48.6 M) | (88 M) | (79.2 M) | (75.3 M) |
| LEGN | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | (2.8 M) | (101.6 M) | (266.4 M) | (403.6 M) | (446.3 M) | (518.3 M) | (177 M) | (159.3 M) | (167.3 M) |
| SLNO | (6.5 M) | (6.5 M) | (6.5 M) | (3.7 M) | (13.9 M) | (15.9 M) | (12.1 M) | (15.7 M) | (13.3 M) | (30.8 M) | (24.6 M) | (30.9 M) | (24.1 M) | (39 M) | (175.8 M) | (158.3 M) | (150.4 M) |
| IRON | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (36 M) | (46.1 M) | (76.4 M) | (109.4 M) | (98.4 M) | (103.3 M) |
Apogee Therapeutics and related stocks such as Centessa Pharmaceuticals, Xenon Pharmaceuticals, and Ascentage Pharma Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Apogee Therapeutics financial statement analysis. It represents the amount of money remaining after all of Apogee Therapeutics Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Apogee Therapeutics Competitive Analysis
The better you understand Apogee Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Apogee Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Apogee Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Apogee Therapeutics Competition Performance Charts
Five steps to successful analysis of Apogee Therapeutics Competition
Apogee Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Apogee Therapeutics in relation to its competition. Apogee Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Apogee Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Apogee Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Apogee Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Apogee Therapeutics position
In addition to having Apogee Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cigarettes Thematic Idea Now
Cigarettes
Tobacco makers and distributors across globe. The Cigarettes theme has 11 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cigarettes Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Apogee Therapeutics Correlation with its peers. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Will Biotechnology sector continue expanding? Could Apogee diversify its offerings? Factors like these will boost the valuation of Apogee Therapeutics. If investors know Apogee will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Apogee Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Apogee Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Apogee Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Apogee Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Apogee Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apogee Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Apogee Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.